Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting
Relmada Therapeutics (Nasdaq: RLMD) announced that data on its lead candidate, REL-1017, will be showcased at the American Society of Clinical Psychopharmacology Annual Meeting from May 31 to June 3, 2022. The poster presentations will discuss human abuse potential studies comparing REL-1017 to ketamine and oxycodone. REL-1017 is under late-stage development as a rapid-acting antidepressant for major depressive disorder (MDD) and has demonstrated significant antidepressant effects in a Phase 2 trial. For more information, visit here.
- None.
- None.
CORAL GABLES, Fla., May 25, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented virtually in two poster presentations at the American Society of Clinical Psychopharmacology 2022 Annual Meeting. The conference is being held Tuesday, May 31, 2022, through Friday, June 3, 2022, in Scottsdale, AZ, and virtually.
The poster presentations will highlight the recently completed human abuse potential (HAP) studies evaluating REL-1017 versus ketamine and oxycodone. The posters are available in the virtual e-Poster gallery to registered attendees. Further details of the posters are as follows:
Virtual Poster Presentations
Title: "No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant"
Title: "No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant"
The posters will be available at https://www.relmada.com/science/data-and-publications at the conclusion of the conference. Further information on the conference can be found here: https://ascpp.org/ascp-meetings/ascp-annual-meeting/.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of major depressive disorder (MDD). The ongoing Reliance Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive and monotherapy treatment for MDD. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
917-679-9282
tim@lifesciadvisors.com
Media Inquiries:
FischTank PR
relmada@fischtankpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-data-at-the-american-society-of-clinical-psychopharmacology-2022-annual-meeting-301554742.html
SOURCE Relmada Therapeutics, Inc.
FAQ
What data will Relmada Therapeutics present at the 2022 Annual Meeting?
When is the American Society of Clinical Psychopharmacology Annual Meeting?
What is REL-1017 and its significance?
Where can I find the poster presentations on REL-1017?
What were the findings regarding REL-1017's abuse potential?
